Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News TScan Therapeutics Inc TCRX

Healthcare Biotechnology
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TCRX)

TScan Therapeutics Announces Positive Updated Data from the ALLOHA(TM) Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire 5 days ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA(TM) Phase 1 Trial and Future Market Opportunities

GlobeNewswire 9 days ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2025

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire November 5, 2025

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

GlobeNewswire November 3, 2025

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

GlobeNewswire September 17, 2025

TScan Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 3, 2025

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2025

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

GlobeNewswire May 28, 2025
View More News ››

Opinion & Analysis (NDAQ:TCRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX): A Promising Biotech

http://beyondsp
MikeTester - August 3, 2024
View more Bullboard ››

Freegold Ventures Limited

Freegold Ventures Limited

Freegold Ventures Limited is a Canada-based company focused on exploration in Alaska. The Company holds the Summit Gold ...
View More »